COPLEY GRAND JURY SUBPOENA RELATES TO BROMPHERIL OTC
This article was originally published in The Tan Sheet
Executive Summary
COPLEY GRAND JURY SUBPOENA RELATES TO BROMPHERIL OTC antihistamine/decongestant combination product, the company disclosed on Sept. 14. The subpoena was handed down by the U.S. Attorney's Office in Boston on Aug. 23. In a Sept. 14 press release, Copley announced a voluntary recall of the extended- release brompheniramine/pseudoephedrine product due to concerns over manufacturing procedures. The Copley brand was the first equivalent to Schering's Drixoral extended-release product to be approved by FDA in January 1987.